---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-000897"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2023-01-04T23:59:59+00:00"
generated_at: "2026-06-20T20:07:39.442910+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Innoviva appoints Dr. Sapna Srivastava to board, effective Jan 1, 2023

## Summary
- Dr. Sapna Srivastava appointed to Board as independent director, effective Jan 1, 2023.
- Srivastava brings experience as former CFO of Intellia Therapeutics and Abide Therapeutics, and 15 years as biotech analyst.
- Received initial RSU award of $125,000, prorated RSU of $56,250, and option for 2,500 shares.
- Annual cash retainer of $50,000 for board service.
- Bylaws amended to remove reference to SmithKline Beecham and update director nomination procedures.

## SEC filing metadata
- accession: 0001104659-23-000897
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2023-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/0001104659-23-000897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/tm231444d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-000897
- JSON: https://secwatch.observer/filing/0001104659-23-000897.json
- Plain text: https://secwatch.observer/filing/0001104659-23-000897.txt

## Key facts
- Executive change
  Sapna Srivastava was appointed as Director at Innoviva, Inc..
  - Action: appointed
  - Role: Director
  source text: On December 29, 2022, Innoviva, Inc. (the “Company”) appointed Sapna Srivastava, Ph. D., to its Board of Directors (the “Board”), effective January 1, 2023 (the “Srivastava Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/0001104659-23-000897-index.htm
- Governance Changes
  Innoviva, Inc.: Amended the Company's by-laws to remove reference to SmithKline Beecham Corporation as a shareholder and update procedures and information requirements for director nominations, including with respect to Rule 14a-19 (effective 2023-01-01).
  - Change: bylaw amendment
  - Effective: 2023-01-01
  source text: On December 31, 2022, the Board amended the Company’s by-laws, effective as of January 1, 2023, to remove reference to SmithKline Beecham Corporation, a Pennsylvania corporation, as a shareholder of the Company and update the procedures and information requirements for the nomination of directors, including with respect to Rule 14a-19 promulgated under the Securities Exchange Act of 1934, as amended.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/0001104659-23-000897-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.